Insulin icodec
- Generic Name
- Insulin icodec
- Brand Names
- Awiqli
- Drug Type
- Biotech
- CAS Number
- 1188379-43-2
- Unique Ingredient Identifier
- P7YU3ED05N
Novel Therapies to Watch in 2025: Oncology, Hematology, and Neurology
• Tarlatamab (Imdelltra) is set to transform small cell lung cancer treatment, targeting DLL3-expressing cells and potentially becoming the standard of care for previously treated ES-SCLC.
• Fitusiran, an antithrombin-targeting siRNA, offers a novel approach to hemophilia A or B treatment, demonstrating significant reductions in annualized bleeding rates in phase 3 trials.
• Vepdegestrant (ARV-471), a PROTAC protein degrader, shows promise in ER+/HER2- metastatic breast cancer, potentially offering a more effective protein degradation mechanism.
• Cobenfy (xanomeline and trospium chloride) represents a new class of schizophrenia treatment, selectively targeting M1 and M4 receptors, with observed improvements in clinical trials.
Novartis and Apellis Advance C3G Therapies Towards FDA Submission
• Novartis' Fabhalta (iptacopan) demonstrated significant proteinuria reduction in the Phase III APPEAR-C3G trial, meeting its primary endpoint and supporting regulatory submissions.
• Apellis' Empaveli (pegcetacoplan) showed a substantial reduction in proteinuria and C3c deposit clearance in the Phase III VALIANT trial, indicating early efficacy in C3G patients.
• Nephrologists express a strong interest in new C3G therapies that can slow eGFR decline and reduce proteinuria, addressing the urgent need for innovative treatments.
• Spherix data suggests treatment preferences may be influenced by administration route, with Fabhalta's oral administration potentially offering an advantage.
Biopharma Sector Shows Recovery: Bristol-Myers Squibb and Gilead Lead Market Gains
• The biopharmaceutical sector is showing signs of recovery, with a 2% rise in combined market capitalization among the top 20 global companies.
• Bristol-Myers Squibb led the recovery with a 24.6% increase in market capitalization, driven by the FDA approval of Cobenfy for schizophrenia.
• Gilead Sciences experienced a 22.1% rise, spurred by FDA approvals for Livdelzi in primary biliary cholangitis and Trodelvy in HR-/HER2- breast cancer.
• Novo Nordisk and Eli Lilly faced setbacks, with Novo Nordisk seeing an 18.2% drop after the FDA rejected its weekly insulin icodec application.
Eli Lilly's Weekly Insulin Efsitora Shows Promise in Phase 3 Trials
• Eli Lilly's efsitora, a weekly insulin injection, demonstrated effectiveness comparable to daily insulin in Phase 3 trials for type 2 diabetes.
• In the QWINT-1 trial, patients new to insulin saw similar A1C reductions with efsitora compared to daily insulin after 52 weeks.
• The QWINT-3 trial showed efsitora also effectively lowered A1C levels in patients previously on daily insulin, with results after 26 weeks.
• Efsitora offers the potential for 313 fewer injections per year, aiming to simplify insulin therapy and improve patient adherence.
Eli Lilly's Efsitora Alfa Shows Promise in Type 2 Diabetes Treatment
• Eli Lilly's efsitora alfa, a once-weekly insulin, demonstrated non-inferiority to daily insulin in Phase 3 trials for type 2 diabetes, meeting its primary endpoint.
• The safety profile of efsitora alfa was consistent with daily insulin, suggesting it could be a viable option for patients seeking less frequent dosing.
• Efsitora alfa aims to compete with Novo Nordisk's once-weekly insulin, Awiqli, in the growing market for diabetes treatments, addressing a significant patient population.
• Despite competition, efsitora alfa represents a potential revenue stream for Eli Lilly, complementing its already strong portfolio and pipeline, including drugs like Verzenio and Mounjaro.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath